Long-term outcome of living-donor liver transplantation for combined hepatocellular-cholangiocarcinoma

Anticancer Res. 2015 Apr;35(4):2475-6.

Abstract

Background/aim: Combined hepatocellular-cholangiocarcinoma (cHC-CC) is found unexpectedly in explanted or resected liver specimens. The current study evaluated the longterm outcomes of living-donor liver transplantation (LDLT) between patients with cHC-CC and hepatocellular carcinoma (HCC).

Patients and methods: We performed 178 LDLT including 8 patients of pathologically and immunohistochemically diagnosed cHC-CC who all underwent LDLT with a preoperative diagnosis of HCC by imaging study.

Results: Out of the 8 patients, 6 were within the Milan criteria and all were within the Kyushu University criteria. The 1-, 5- and 10-year overall survival (OS) and disease-free survival (DFS) rates after LDLT for patients with cHC-CC were 87.5, 72.9 and 48.6% and 85.7, 85.7 and 85.7%, respectively. The OS and DFS between patients with cHC-CC and HCC were not statistically different.

Conclusion: LDLT for patients with cHC-CC using the Milan criteria or the Kyushu University criteria, as well as HCC, could have an acceptable long-term outcome.

Keywords: Combined hepatocellular-cholangiocarcinoma; hepatocellular carcinoma; living-donor liver transplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Hepatocellular / pathology*
  • Cholangiocarcinoma / etiology
  • Cholangiocarcinoma / pathology*
  • Disease-Free Survival
  • Female
  • Humans
  • Liver Neoplasms / pathology*
  • Liver Transplantation / adverse effects*
  • Living Donors
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / etiology
  • Neoplasm Recurrence, Local / pathology*
  • Treatment Outcome